Multi-Gene Pathway Analysis Reveals Complex II Dependence in Aggressive Leukemic Cells

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature Metabolism https://doi.org/10.1038/s42255-025-01410-x 
Dr. Amy E. Stewart  et al.

Points

Researchers utilized a novel computational tool to analyze interactions among three thousand gene sets and discovered a critical metabolic dependency in acute myeloid leukemia.
The study identified that mitochondrial Complex II regulates the flow of nitrogen from glutamine to glutamate to support the de novo biosynthesis of purines.
Inhibition of Complex II in syngeneic mouse models resulted in significant tumor regression and extended survival by cutting off the supply of DNA building blocks.
Elevated levels of Complex II gene expression in patients were found to correlate with resistance to BCL-2 inhibition and poorer overall survival outcomes.
This metabolic vulnerability offers a therapeutic target that selectively kills leukemic cells while sparing normal tissues that utilize alternative nutrient acquisition pathways.

Summary

This study utilized a novel multi-gene computational framework to map pathway interactions across approximately 3,000 gene sets and nearly 15,000 genes, identifying a critical metabolic dependency in acute myeloid leukemia (AML). The analysis revealed that AML cells rely heavily on mitochondrial Complex II to support de novo purine biosynthesis, a process essential for generating the DNA and RNA building blocks required for rapid proliferation. Stable-isotope metabolomic tracing demonstrated that Complex II metabolizes glutamate derived from glutamine, thereby sustaining the nitrogen supply necessary for the purine ring structure.

In syngeneic AML mouse models, the specific inhibition of Complex II resulted in rapid tumor regression and extended overall survival. The mechanism involves a metabolic circuit where increasing intracellular glutamate levels suppresses purine production, effectively sensitizing leukemic cells to Complex II inhibition. Unlike normal cells, which possess alternative nutrient acquisition pathways, AML cells lack this metabolic flexibility, suggesting that targeting this pathway could offer a high therapeutic index by inducing selective cancer cell death while sparing healthy tissues.

Clinical data analysis indicated that elevated Complex II gene expression correlates with resistance to BCL-2 inhibition and poorer survival outcomes in patients. These findings establish Complex II not only as a central regulator of purine metabolism but also as a potential biomarker for risk stratification. The study suggests that pharmacological disruption of this metabolic circuit, potentially combined with existing regimens, represents a viable therapeutic strategy for overcoming drug resistance in aggressive blood cancers.

Link to the article: https://www.nature.com/articles/s42255-025-01410-x

References

Stewart, A. E., Zachman, D. K., Castellano-Escuder, P., Kelly, L. M., Zolyomi, B., Aiduk, M. D. I., Delaney, C. D., Lock, I. C., Bosc, C., Bradley, J., Killarney, S. T., Stuart, J. D., Grimsrud, P. A., Ilkayeva, O. R., Newgard, C. B., Chandel, N. S., Puissant, A., Wood, K. C., & Hirschey, M. D. (2025). Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia. Nature Metabolism, 1–15. https://doi.org/10.1038/s42255-025-01410-x